Penn Med-led Cardiovascular Health Screening Technology Receives Development Funding From AHA

facebook twitter google print email
Media Contact:Karen Kreeger | | 215-349-5658
Media Contact:Jessica Mikulski | | 215-349-8360May 9, 2012

The American Heart Association (AHA) announced today that they have made their first investment through the Science & Technology Accelerator Program into CytoVas, LLC. The company was founded by Jonni S. Moore, PhD, and Wade Rogers, PhD, Department of Pathology and Laboratory Medicine, and Emile R. Mohler III, MD, Department of Medicine, Cardiovascular Division, faculty members of the Perelman School of Medicine at the University of Pennsylvania, and will further develop research into a screen for a patient's vascular health profile. This new investment program was inaugurated by the AHA to bridge the gap from research to commercialization and bring potentially life-saving diagnostics and treatments to patients more rapidly.

The vascular health profile, currently being developed by CytoVas, measures major indicators of blood vessel health: the number of blood-vessel stem cells and the amount of microparticles, created through the natural cycle of cell death and renewal. More stem cells indicate that blood vessels have an enhanced ability to respond to changes in the body and regenerate in response to injury. High levels of microparticles appear toxic and are thought to contribute to hardening of the arteries and heart attack and stroke. Therefore, the balance of those two components is potentially of significant clinical use as an index of blood vessel health. Since nearly half of the people who have cardiovascular health problems aren't considered at high risk by most commonly used heart-health profiles, there's an urgent need to provide a comprehensive snapshot of blood-vessel damage and the reparative capacity of the body.

The AHA funds will be used by CytoVas for the next phase of development, a clinical study, which will determine whether the test can be used to monitor the effects of statin treatment.

If successful, this technology would first be used by pharmaceutical and biotech companies for drug development and clinical trials to identify cardiovascular side effects of new drugs and to identify patients who may respond particularly well to a new treatment. Ultimately, the test will be used to assess people without heart-disease symptoms who are being considered for cardiovascular preventive treatment, or for routine monitoring of the effectiveness of treatments for people who have cardiovascular disease.

Click here to view the full release.